Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people notice shifts in their menstrual cycle after starting Wegovy. Period changes on semaglutide are not listed as a direct side effect in the medicine's official labelling, but there are plausible biological reasons they happen — and most resolve as the body adjusts. This page covers what is known, what remains uncertain, and when it is worth talking to a clinician. Wegovy (semaglutide) is a prescription-only medicine; a qualified prescriber assesses suitability before any treatment begins. You can read more about the medicine itself on the Wegovy overview page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy does not act on reproductive hormones directly. Semaglutide works by activating GLP-1 receptors involved in appetite regulation and gastric emptying, which leads to a sustained reduction in calorie intake. The link to menstrual changes runs through a different route: body fat.
Fat tissue is an active endocrine organ. It produces and stores oestrogen, and when fat mass falls relatively quickly (as it often does during the early months on a GLP-1 medicine) oestrogen levels can shift. The hypothalamic-pituitary axis, which governs the hormonal signals behind ovulation, is sensitive to these changes. A drop in available oestrogen, or disrupted signalling between the brain and the ovaries, can shorten, lengthen or temporarily suspend the cycle. This is the same mechanism that explains why people who lose weight through any method (surgery, diet, intensive exercise) sometimes notice cycle irregularity.
There is also an indirect effect through conditions like polycystic ovary syndrome (PCOS). PCOS is strongly associated with insulin resistance and excess body weight; as weight falls on treatment, insulin sensitivity often improves, and for people with previously irregular cycles driven by PCOS, periods can actually become more regular. So the direction of change varies: some people find their cycle settles, others find it becomes temporarily unpredictable. The question of whether Wegovy changes your period depends considerably on your starting point.
The NHS guidance on weight-management injections notes that hormonal changes during treatment are worth discussing with your prescriber, particularly around contraception and fertility.
A missed period or a significant gap between cycles is the change that tends to worry people most. It is genuinely possible on semaglutide, particularly in the first few months when weight loss tends to be fastest. Rapid changes in body composition can suppress ovulation (a state clinicians call hypothalamic amenorrhoea) and the cycle pauses until the body stabilises.
If you miss a period, the first practical step is a pregnancy test. This is not alarmist: as weight falls and metabolic health improves, fertility often increases, sometimes before the person on treatment realises it. People who had irregular or absent periods due to obesity-related hormonal disruption may find their cycle (and their fertility) returning unpredictably. Our page on no period while taking Wegovy goes into this in more detail, including when absence of a period is more likely to be treatment-related versus something to investigate further.
Lighter periods, heavier periods and spotting between cycles have all been reported anecdotally by people on semaglutide, though large-scale trial data specifically on menstrual patterns is limited. The STEP 1 trial (68 weeks, around 2,000 participants) captured body weight, cardiometabolic markers and side-effect profiles but was not designed to track menstrual cycle data systematically. That absence of trial data does not mean the experiences are not real; it means the evidence base is still catching up.
Persistent irregularity beyond three to four months, or any bleeding that is unusually heavy or accompanied by pain, should be discussed with a GP rather than attributed to the medicine alone.
This is probably the most practically important section on this page. Improved fertility is a real and documented consequence of weight loss in people with obesity-related hormonal disruption. If pregnancy is not the goal, contraception needs attention before treatment begins, not after the first missed period.
For people using oral contraceptive pills alongside Wegovy, there is a specific consideration. The NHS England guidance on weight-management injections advises that semaglutide's effect on gastric emptying could theoretically reduce pill absorption during periods of gastrointestinal side effects (nausea, vomiting). The current evidence is less definitive for semaglutide than it is for tirzepatide, but the precautionary advice is to use an additional contraceptive method (condoms, for example) whenever GI symptoms are significant, and to discuss options with a prescriber or GP.
If you are trying to conceive, Wegovy is not recommended during pregnancy or while attempting to become pregnant. The washout period before trying to conceive should be discussed with a prescriber; this is not something to self-manage. People who are breastfeeding or pregnant should not use semaglutide. Detailed guidance is covered in the period and Wegovy clinical overview.
The NHS England guidance on weight-management injections addresses the contraception question specifically, and it is worth reading before or during treatment if this applies to you.
Most cycle changes in the first few months of treatment are benign and self-resolving. A useful benchmark: if your cycle was broadly regular before starting Wegovy and becomes irregular in the first eight to twelve weeks, that is common and worth monitoring but not immediately alarming. If things have not settled by month four, a GP review is sensible.
Contact a doctor promptly rather than waiting if you experience: a missed period alongside a negative pregnancy test and no obvious explanation; bleeding that soaks through a pad or tampon in under an hour for several hours consecutively; pain severe enough to interrupt daily activity; any new bleeding after menopause. These patterns can have causes that are entirely unrelated to semaglutide and need their own assessment.
Semaglutide can also affect other body systems in ways worth knowing about, our page on Wegovy and vision changes covers one less-discussed area, and physical changes linked to semaglutide explores others. You can also read about semaglutide's effects on digestion, which are closely related to the GI mechanisms discussed above.
If you have questions about whether treatment is right for your situation, our clinical team reviews every consultation personally. Any concerns about side effects during treatment can be raised through our priority aftercare, available seven days a week. You can also get in touch directly if you need to speak to someone. We know timing matters, if you are planning treatment around a holiday or a busy month, the free consultation is there whenever you are ready. Check your eligibility and start your free consultation when the moment is right for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.